World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
110
Citations
51613
World Ranking
5494
National Ranking
2961

Overview

Walter M. Stadler is affiliated with the University of Chicago in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with notable contributions in subfields such as Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Economics and Econometrics.

The scientist's work focuses on several key topics, including:

  • Renal cell carcinoma treatment
  • Prostate Cancer Treatment and Research
  • Renal and related cancers
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Pancreatic and Hepatic Oncology Research
  • Radiopharmaceutical Chemistry and Applications

Walter M. Stadler has contributed to multiple peer-reviewed research papers. Among their recent publications are:

  • Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma, 2022, JAMA Oncology
  • Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE), 2020, Journal of Clinical Oncology
  • Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma, 2024, New England Journal of Medicine
  • Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer, 2022, JAMA Oncology
  • Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC), 2021, Cancer

Their frequent co-authors include:

  • Russell Z. Szmulewitz
  • Christian Kollmannsberger
  • Toni K. Choueiri
  • Laurence Albigès
  • Brian I. Rini

Publications by Walter M. Stadler appear notably in the following venues:

  • Journal of Clinical Oncology
  • Cancer
  • Clinical Cancer Research
  • JAMA Oncology
  • Clinical Genitourinary Cancer

Best Publications

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

    Michael B. Atkins;Manuel Hidalgo;Walter M. Stadler;Theodore F. Logan

  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

    Brian I Rini;Thomas Powles;Michael B Atkins;Bernard Escudier

  • Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

    Brian I Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

    Brian I. Rini;Susan Halabi;Jonathan E. Rosenberg;Walter M. Stadler

  • Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Ezra E. W. Cohen;Fred Rosen;Walter M. Stadler;Wendy Recant

  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

    Eric J. Small;Susan Halabi;Nancy A. Dawson;Walter M. Stadler

  • Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

    Naomi B. Haas;Judith Manola;Robert G. Uzzo;Keith T. Flaherty

  • Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

    Hedy L. Kindler;Gregory Friberg;Deepti A. Singh;Gershon Locker

  • Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers

    Gladell P. Paner;Walter M. Stadler;Donna E. Hansel;Rodolfo Montironi

  • Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663

    Mary-Ellen Taplin;Barur Rajeshkumar;Susan Halabi;Cary P. Werner

  • Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells

    Henry K. Lin;Siyang Zheng;Anthony J. Williams;Marija Balic

  • Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

    B. Escudier;C. Szczylik;T. Eisen;W. M. Stadler

  • Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

    Daniel V.T. Catenacci;Melissa R. Junttila;Theodore Karrison;Nathan Bahary

  • Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

    Brian I. Rini;M. Dror Michaelson;Jonathan E. Rosenberg;Ronald M. Bukowski

  • Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

    Brian I. Rini;George Wilding;Gary Hudes;Walter M. Stadler

Frequent Co-Authors

Theodore Karrison
Theodore Karrison University of Chicago
Mark J. Ratain
Mark J. Ratain University of Chicago
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Susan Halabi
Susan Halabi Duke University
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Toni K. Choueiri
Toni K. Choueiri Harvard University
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
Everett E. Vokes
Everett E. Vokes University of Chicago
Daniel J. George
Daniel J. George Duke University
Eric J. Small
Eric J. Small University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in Medicine opens doors to numerous online education and career options in the healthcare field. For those interested in medical administration, medical billing and coding classes online offer a fast-track into back-office healthcare roles, providing foundational knowledge at a flexible pace and often at an affordable cost.

If your career goals involve becoming an advanced practice nurse, consider the cheapest np school online. Online nurse practitioner programs combine rigorous coursework with accessible online formats, allowing you to balance studies with work or family commitments.

For registered nurses aiming to advance their education, explore the cheapest online msn programs. These degrees help expand your expertise in specialized nursing fields and open up leadership roles.

Want to reach the highest level in nursing? The cheapest dnp programs online are ideal for those looking to lead, teach, or influence health policy and practice. Each online pathway offers unique advantages, helping you build a meaningful and successful healthcare career.

Best Scientists Citing Walter M. Stadler

Trending Scientists

Recently Published Articles